<DOC>
	<DOCNO>NCT01288989</DOCNO>
	<brief_summary>A dose escalation study determine safety maximum tolerate dose ( MTD ) IMC-3C5 subject advance solid tumor refractory standard therapy standard therapy available .</brief_summary>
	<brief_title>A Study Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>This multicenter study enroll approximately 40 subject . The actual sample size vary depend many subject need obtain least 3 complete subject per cohort . IMC-3C5 initially administer every week ( Cohorts 1-4 ) dose escalate manner . The start dose 5mg/kg weekly ( Cohort 1 ) . Dose escalation proceed 10mg/kg ( Cohort 2 ) , 20 mg/kg ( Cohort 3 ) , 30mg/kg ( Cohort 4 ) . Based analysis safety pharmacokinetic profile weekly dosing , subject may enrol sequentially 2 every-other-week dose cohort ( Cohorts 5-6 , 20mg/kg 30mg/kg ) . Intermediate dos may also use .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subject histologic cytologic confirmation cancer 2 . Subject advance solid tumor refractory standard therapy standard therapy available 3 . Subject measurable nonmeasurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 4 . Subject receive prior chemotherapy prior treatment investigational agent device within 28 day prior enrollment ( hormone therapy acceptable ) 5 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status 0,1 , 2 6 . Subject adequate hematologic , hepatic , renal , coagulation function 7 . Subject life expectancy great 3 month 8 . Subject agree use adequate contraception study period 12 week last dose investigational agent 1 . Subject know sensitivity monoclonal antibody therapeutic protein , agent similar biologic composition IMC3C5 2 . Subject receive treatment monoclonal antibody include bevacizumab within 6 week prior enrollment 3 . Subject undergone major surgical procedure , radiation therapy , open biopsy , experience significant injury within 28 day prior enrollment 4 . Subject ongoing active infection ( except outline Exclusion Criterion # 11 ) , congestive heart failure , active bleed serious uncontrolled medical disorder 5 . Subject know suspected untreated brain leptomeningeal metastases 6 . Subject uncontrolled hypertension 7 . Subject receive organ transplant 8 . Subject serious nonhealing wound , ulcer , bone fracture 9 . Subject experienced arterial venous thromboembolic event within 6 month prior enrollment 10 . Subject currently peripheral edema require diuresis anasarca 11 . Subject Human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) , except subject stable antiviral regimen least 12 week , viral load &lt; 50 copies/mL , CD4 count â‰¥ 200 cells/mm3 12 . Subject currently use receive thrombolytic agent within 28 day prior enrollment 13 . Subject receive aspirin dose high 325 mg per day fulldose anticoagulation 14 . Subject female , pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>